Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of EQU-001 in drug-resistant epilepsy
MOH_2021-12-08_010184Phase 2Completed
- Sponsor
- Equilibre Biopharmaceuticals
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing EQU-001 treatment arm with Placebo arm (2 arms). Primary endpoint: Safety across the dose range of EQU-001. Started Aug 2021; status: completed.
02
Drugs
equ-001
03
Conditions
epilepsy
Beyond the preview
Go deeper on MOH_2021-12-08_010184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-08_010184.